p53 as a prognostic factor for stage III serous adenocarcinoma of the ovary.
Expression of mutant p53 in 19 patients with stage III moderately differentiated serous cystadenocarcinoma of the ovary, who all had optimal primary cytoreductive surgery and six cycles of cisplatin and cyclophosphamide was analyzed to determine its prognostic significance. All patients were followed up for a minimum of 48 months. Immunohistochemical analysis for mutant p53 was by means of monoclonal antibody DO7 and Pab240. Mean survival for patients expressing mutant p53 was 44 months and 117 months for those not expressing mutant p53. In our study, expression of mutant p53 proved to be a statistically adverse prognostic factor (p = 0.029).
Daponte
A
A
Department of Obstetrics and Gynaecology, Johannesburg Hospital, University of the Witwatersrand, South Africa.
Guidozi
F
F
Tiltman
A J
AJ
Marineanu
A
A
Taylor
L
L
D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology* / Q000601:surgery; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D016158:Genes, p53; D006801:Humans; D009154:Mutation; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology* / Q000601:surgery; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D016159:Tumor Suppressor Protein p53 / Q000032:analysis / Q000235:genetics*
D016159:Tumor Suppressor Protein p53; D003520:Cyclophosphamide; D002945:Cisplatin